astrazeneca hit by drug failure shares in anglo swedish drug have closed down 8% in uk trade after the failure of its iressa drug in a major clinical trial. i am determined to improve our development and regulatory performance, restore confidence in the company and value to shareholders, said chief executive tom mckillop.